Publications

List of publications, Jakob Seidelin, PubMed search Jan 1st, 2023.

For updated publication list look here.

  1. Holmstroem RB, Dahl EK, Helms M, Nielsen HV, Andersen JB, Bjerrum JT, Svane IM, Ellebaek E, Seidelin JB. Tofacitinib and faecal microbiota transplantation in treating checkpoint inhibitor-induced enterocolitis: case report. BMJ Open Gastroenterol. 2022 Dec;9(1):e000989. doi: 10.1136/bmjgast-2022-000989. PMID: 36581371
  2. Dahl EK, Abed OK, Kjeldsen J, Donia M, Svane IM, Dige A, Agnholt JS, Bjerrum JT, Seidelin JB. Safety and efficacy of infliximab and corticosteroids in checkpoint inhibitor-induced colitis-authors’ reply. Aliment Pharmacol Ther. 2023 Jan;57(1):152-153. doi: 10.1111/apt.17250. Epub 2022 Dec 5. PMID: 36468203
  3. Attauabi M, Seidelin JB, Burisch J. Reply to comment on: Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn’s disease – a systematic review with meta-analysis. Dig Liver Dis. 2022 Dec 1:S1590-8658(22)00786-1. doi: 10.1016/j.dld.2022.11.009. Online ahead of print. PMID: 36464612
  4. Démaris A, Widigson ESK, Ilvemark JFKF, Steenholdt C, Seidelin JB, Huisinga W, Michelet R, Aulin LBS, Kloft C. Ulcerative Colitis and Acute Severe Ulcerative Colitis Patients Are Overlooked in Infliximab Population Pharmacokinetic Models: Results from a Comprehensive Review. Pharmaceutics. 2022 Sep 30;14(10):2095. doi: 10.3390/pharmaceutics14102095. PMID: 36297530
  5. Kann AE, Ba-Ali S, Seidelin JB, Larsen FS, Hamann S, Bjerring PN. The effect of induced hyperammonaemia on sleep and melanopsin-mediated pupillary light response in patients with liver cirrhosis: A single-blinded randomized crossover trial. PLoS One. 2022 Sep 28;17(9):e0275067. doi: 10.1371/journal.pone.0275067. eCollection 2022. PMID: 36170326
  6. Wewer MD, Langholz E, Munkholm P, Bendtsen F, Seidelin JB, Burisch J. Disease Activity Patterns of Inflammatory Bowel Disease – A Danish Nationwide Cohort Study 1995-2018. J Crohns Colitis. 2022 Sep 19:jjac140. doi: 10.1093/ecco-jcc/jjac140. Online ahead of print. PMID: 3612489
  7. Dahl EK, Abed OK, Kjeldsen J, Donia M, Svane IM, Dige A, Agnholt JS, Bjerrum JT, Seidelin JB. Safety and efficacy of infliximab and corticosteroid therapy in checkpoint inhibitor-induced colitis. Aliment Pharmacol Ther. 2022 Nov;56(9):1370-1382. doi: 10.1111/apt.17201. Epub 2022 Sep 19. PMID: 36123319
  8. Attauabi M, Madsen GR, Bendtsen F, Wewer AV, Wilkens R, Ilvemark J, Vladimirova N, Jensen AB, Jensen FK, Hansen SB, Siebner HR, Nielsen YJW, Møller JM, Thomsen HS, Thomsen SF, Ingels HAS, Theede K, Boysen T, Bjerrum JT, Jakobsen C, Dorn-Rasmussen M, Jansson S, Yao Y, Burian EA, Møller FT, Fana V, Wiell C, Terslev L, Østergaard M, Bertl K, Stavropoulos A, Seidelin JB, Burisch J. Influence of Genetics, Immunity and the Microbiome on the Prognosis of Inflammatory Bowel Disease (IBD Prognosis Study): the protocol for a Copenhagen IBD Inception Cohort Study. BMJ Open. 2022 Jun 27;12(6):e055779. doi: 10.1136/bmjopen-2021-055779. PMID: 35760545
  9. Ilvemark JFKF, Wilkens R, Thielsen P, Dige A, Boysen T, Brynskov J, Bjerrum JT, Seidelin JB. Early intestinal ultrasound predicts intravenous corticosteroid response in hospitalized patients with severe ulcerative colitis. J Crohns Colitis. 2022 Jun 13:jjac083. doi: 10.1093/ecco-jcc/jjac083. Epub ahead of print. PMID: 35695823.
  10. Ilvemark JFKF, Hansen T, Goodsall TM, Seidelin JB, Al-Farhan H, Allocca M, Begun J, Bryant RV, Carter D, Christensen B, Dubinsky MC, Gecse KB, Kucharzik T, Lu C, Maaser C, Maconi G, Nylund K, Palmela C, Wilson SR, Novak K, Wilkens R. Defining Transabdominal Intestinal Ultrasound Treatment Response and Remission in Inflammatory Bowel Disease: Systematic Review and Expert Consensus Statement. J Crohns Colitis. 2022 May 10;16(4):554-580. doi: 10.1093/ecco-jcc/jjab173. PMID: 34614172; PMCID: PMC9089416.
  11. Attauabi M, Dahlerup JF, Poulsen A, Hansen MR, Vester-Andersen MK, Prahm AP, Pedersen N, Larsen L, Jess T, Neumann A, Haderslev KV, Molazahi A, Lødrup AB, Glerup H, Oppfeldt AM, Jensen MD, Theede K, Kiszka-Kanowitz M, Seidelin JB, Burisch J. Association Between the Clinical, Biochemical, and Endoscopic Activity of Inflammatory Bowel Diseases and Severity and Long-term Outcomes of Coronavirus Disease 2019-A Population-based Study. Inflamm Bowel Dis. 2022 Mar 24:izac052. doi: 10.1093/ibd/izac052. Epub ahead of print. PMID: 35325137; PMCID: PMC8992288.
  12. Zhao M, Wewer MD, Bjerrum JT, Steenholdt C, Schiødt F, Haderslev K, Kiszka- Kanowitz M, Munkholm P, Seidelin J, Burisch J. [Practical guide to the use of thiopurinesin patients with inflammatory bowel diseases]. Ugeskr Laeger. 2022 Mar 14;184(11):V09210706. Danish. PMID: 35315759.
  13. Bjerrum JT, Wang Y, Zhang J, Riis LB, Nielsen OH, Seidelin JB. Lipidomic Trajectories Characterize Delayed Mucosal Wound Healing in Quiescent Ulcerative Colitis and Identify Potential Novel Therapeutic Targets. Int J Biol Sci. 2022 Feb 14;18(5):1813-1828. doi: 10.7150/ijbs.67112. PMID: 35342362; PMCID: PMC8935238.
  14. Attauabi M, Wewer MD, Bendtsen F, Seidelin JB, Burisch J. Inflammatory Bowel Diseases Affect the Phenotype and Disease Course of Coexisting Immune-Mediated Inflammatory Diseases: A Systematic Review With Meta-Analysis. Inflamm Bowel Dis. 2022 Feb 4:izac003. doi: 10.1093/ibd/izac003. Epub ahead of print. PMID: 35134921.
  15. Peyrin-Biroulet L, Hart A, Bossuyt P, Long M, Allez M, Juillerat P, Armuzzi A, Loftus EV Jr, Ostad-Saffari E, Scalori A, Oh YS, Tole S, Chai A, Pulley J, Lacey S, Sandborn WJ; HICKORY Study Group. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. Lancet Gastroenterol Hepatol. 2022 Feb;7(2):128-140. doi: 10.1016/S2468-1253(21)00298-3. Epub 2021 Nov 17. PMID: 34798039.
  16. Vermeire S, Lakatos PL, Ritter T, Hanauer S, Bressler B, Khanna R, Isaacs K, Shah S, Kadva A, Tyrrell H, Oh YS, Tole S, Chai A, Pulley J, Eden C, Zhang W, Feagan BG; LAUREL Study Group. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. Lancet Gastroenterol Hepatol. 2022 Jan;7(1):28-37. doi: 10.1016/S2468-1253(21)00295-8. Epub 2021 Nov 17. PMID: 34798037.
  17. Attauabi M, Madsen GR, Bendtsen F, Seidelin JB, Burisch J. Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn’s disease – a systematic review with meta-analysis. Dig Liver Dis. 2021 Dec 10:S1590-8658(21)00856-2. doi: 10.1016/j.dld.2021.11.014. Epub ahead of print. PMID: 34903497.
  18. Attauabi M, Vind I, Pedersen G, Bendtsen F, Seidelin JB, Burisch J. Short and long-term effectiveness and safety of vedolizumab in treatment-refractory patients with ulcerative colitis and Crohn’s disease – a real-world two-center cohort study. Eur J Gastroenterol Hepatol. 2021 Dec 1;33(1S Suppl 1):e709-e718. doi: 10.1097/MEG.0000000000002229. PMID: 34101681.
  19. Attauabi M, Dahlerup JF, Poulsen A, Hansen MR, Verner-Andersen MK, Eraslan S, Prahm AP, Pedersen N, Larsen L, Jess T, Neumann A, Haderslev KV, Molazahi A, Lødrup AB, Glerup H, Oppfeldt AM, Jensen MD, Theede K, Kiszka-Kanowitz M, Seidelin JB*, Burisch J. Outcomes and long-term effects of COVID-19 in patients with inflammatory bowel diseases – a Danish prospective population-based cohort study with individual-level data. J Crohns Colitis. 2021 Nov 10:jjab192. doi: 10.1093/ecco-jcc/jjab192. Epub ahead of print. PMID: 34755858; PMCID: PMC8689957.
    *Shared senior authorship.
  20. Attauabi M, Seidelin J, Burisch J; Danish COVID-IBD Study Group. Association between 5-aminosalicylates in patients with IBD and risk of severe COVID-19: an artefactual result of research methodology? Gut. 2021 Oct;70(10):2020-2022. doi: 10.1136/gutjnl-2021-324397. Epub 2021 Mar 3. PMID: 33658323.
  21. Bjerrum JT, Wang YL, Seidelin JB, Nielsen OH. IBD metabonomics predicts phenotype, disease course, and treatment response. EBioMedicine. 2021 Sep;71:103551. doi: 10.1016/j.ebiom.2021.103551. Epub 2021 Aug 19. PMID: 34419930; PMCID: PMC8379620.
  22. Attauabi M, Höglund C, Fassov J, Pedersen KB, Hansen HB, Wildt S, Jensen MD, Neumann A, Lind C, Jacobsen HA, Popa AM, Kjeldsen J, Pedersen N, Molazahi A, Haderslev K, Aalykke C, Knudsen T, Cebula W, Munkholm P, Bendtsen F, Seidelin JB, Burisch J. Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases. Scand J Gastroenterol. 2021 Sep;56(9):1040-1048. doi: 10.1080/00365521.2021.1946588. Epub 2021 Jul 5. PMID: 34224299.
  23. Albshesh A, Taylor J, Savarino EV, Truyens M, Armuzzi A, Ribaldone DG, Shitrit AB, Fibelman M, Molander P, Liefferinckx C, Nancey S, Korani M, Rutka M, Barreiro-de Acosta M, Domislovic V, Suris G, Eriksson C, Alves C, Mpitouli A, di Jiang C, Tepeš K, Coletta M, Foteinogiannopoulou K, Gisbert JP, Amir-Barak H, Attauabi M, Seidelin J, Afif W, Marinelli C, Lobaton T, Pugliese D, Maharshak N, Cremer A, Limdi JK, Molnár T, Otero-Alvarin B, Krznaric Z, Magro F, Karmiris K, Raine T, Drobne D, Koutroubakis I, Chaparro M, Yanai H, Burisch J, Kopylov U. Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi- Center Retrospective Cohort Study. J Clin Med. 2021 Jun 29;10(13):2914. doi: 10.3390/jcm10132914. PMID: 34209880; PMCID: PMC8268494.
  24. Attauabi M, Seidelin JB, Burisch J. Authors’ Reply to: ‘COVID-19 in the IBD Population: The Need for Correct Nomenclature’. J Crohns Colitis. 2021 Jun 22;15(6):1080. doi: 10.1093/ecco-jcc/jjaa240. PMID: 33215634; PMCID: PMC7717207.
  25. Larsen S, Seidelin JB, Davidsen J, Dahlgaard K, Nielsen CH, Bennett EP, Pedersen OB, Coskun M, Troelsen JT. CDX2 regulates interleukin-33 gene expression in intestinal epithelial cells (LS174T). FEBS Open Bio. 2021 Jun;11(6):1638-1644. doi: 10.1002/2211-5463.13161. Epub 2021 May 2. PMID: 33838073; PMCID: PMC8167865.
  26. Pauwels RWM, van der Woude CJ, Nieboer D, Steyerberg EW, Casanova MJ, Gisbert JP, Kennedy NA, Lees CW, Louis E, Molnár T, Szántó K, Leo E, Bots S, Downey R, Lukas M, Lin WC, Amiot A, Lu C, Roblin X, Farkas K, Seidelin JB, Duijvestein M, D’Haens GR, de Vries AC; CEASE Study Group. Prediction of Relapse After Anti-Tumor Necrosis Factor Cessation in Crohn’s Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies. Clin Gastroenterol Hepatol. 2021 Apr 30:S1542-3565(21)00347-5. doi: 10.1016/j.cgh.2021.03.037. Epub ahead of print. PMID: 33933376.
  27. Attauabi M, Poulsen A, Theede K, Pedersen N, Larsen L, Jess T, Rosager Hansen M, Verner-Andersen MK, V Haderslev K, Berg Lødrup A, Molazahi A, Neumann A, Wase A, Seidelin JB, Burisch J. Prevalence and Outcomes of COVID-19 Among Patients With Inflammatory Bowel Disease-A Danish Prospective Population-based Cohort Study. J Crohns Colitis. 2021 Apr 6;15(4):540-550. doi: 10.1093/ecco- jcc/jjaa205. PMID: 33035299; PMCID: PMC7797764.
  28. Attauabi M, Seidelin JB, Felding OK, Wewer MD, Vinther Arp LK, Sarikaya MZ, Egeberg A, Vladimirova N, Bendtsen F, Burisch J. Coronavirus disease 2019, immune-mediated inflammatory diseases and immunosuppressive therapies – A Danish population-based cohort study. J Autoimmun. 2021 Mar;118:102613. doi: 10.1016/j.jaut.2021.102613. Epub 2021 Feb 12. PMID: 33592545; PMCID: PMC7879155.
  29. Attauabi M, Burisch J, Seidelin JB. Efficacy of Ustekinumab for Active Perianal Fistulizing Crohn Disease: A Double-Center Cohort Study. Inflamm Bowel Dis. 2021 Feb 16;27(3):e37-e38. doi: 10.1093/ibd/izaa297. PMID: 33200769.
  30. Wewer MD, Zhao M, Nordholm-Carstensen A, Weimers P, Seidelin JB, Burisch J. The Incidence and Disease Course of Perianal Crohn’s Disease: A Danish Nationwide Cohort Study, 1997-2015. J Crohns Colitis. 2021 Jan 13;15(1):5-13. doi: 10.1093/ecco-jcc/jjaa118. PMID: 32582937
  31. Seidelin JB, Bahl MI, Licht TR, Mead BE, Karp JM, Johansen JV, Riis LB, Galera MR, Woetmann A, Bjerrum JT. Acute Experimental Barrier Injury Triggers Ulcerative Colitis-Specific Innate Hyperresponsiveness and Ulcerative Colitis- Type Microbiome Changes in Humans. Cell Mol Gastroenterol Hepatol. 2021;12(4):1281-1296. doi: 10.1016/j.jcmgh.2021.06.002. Epub 2021 Jun 9. PMID: 34118489; PMCID: PMC8455368.
  32. Attauabi M, Burisch J, Seidelin JB. Efficacy of ustekinumab for active perianal fistulizing Crohn’s disease: a systematic review and meta-analysis of the current literature. Scand J Gastroenterol. 2021 Jan;56(1):53-58. doi: 10.1080/00365521.2020.1854848. Epub 2020 Dec 2. PMID: 33264569.
  33. Bergenheim F, Fregni G, Buchanan CF, Riis LB, Heulot M, Touati J, Seidelin JB*, Rizzi SC, Nielsen OH. A fully defined 3D matrix for ex vivo expansion of human colonic organoids from biopsy tissue. Biomaterials. 2020 Dec;262:120248. doi: 10.1016/j.biomaterials.2020.120248. Epub 2020 Aug 19. PMID: 32891909. *Shared senior authorship.
  34. Zhao M, Bendtsen F, Petersen AM, Larsen L, Dige A, Hvas C, Seidelin JB, Burisch J. Predictors of response and disease course in patients with inflammatory bowel disease treated with biological therapy-the Danish IBD Biobank Project: protocol for a multicentre prospective cohort study. BMJ Open. 2020 Feb 25;10(2):e035756. doi: 10.1136/bmjopen-2019-035756. PMID: 32102828; PMCID: PMC7045223.
  35. Jensen S, Seidelin JB, LaCasse EC, Nielsen OH. SMAC mimetics and RIPK inhibitors as therapeutics for chronic inflammatory diseases. Sci Signal. 2020 Feb 18;13(619):eaax8295. doi: 10.1126/scisignal.aax8295. PMID: 32071170.
    *Corresponding author
  36. Seidelin JB, Riis LB, Butt RA. Crohn’s Disease With Progressive Renal Impairment. Gastroenterology. 2020 Jan;158(1):58-59. doi: 10.1053/j.gastro.2019.09.012. Epub 2019 Sep 26. PMID: 31563621.
  37. Bergenheim F, Seidelin JB, Pedersen MT, Mead BE, Jensen KB, Karp JM, Nielsen OH. Fluorescence-based tracing of transplanted intestinal epithelial cells using confocal laser endomicroscopy. Stem Cell Res Ther. 2019 May 27;10(1):148. doi: 10.1186/s13287-019-1246-5. PMID: 31133056; PMCID: PMC6537188.
  38. Li Y, Soendergaard C, Bergenheim FH, Aronoff DM, Milne G, Riis LB, Seidelin JB, Jensen KB, Nielsen OH. COX-2-PGE2 Signaling Impairs Intestinal Epithelial Regeneration and Associates with TNF Inhibitor Responsiveness in Ulcerative Colitis. EBioMedicine. 2018 Oct;36:497-507. doi: 10.1016/j.ebiom.2018.08.040. Epub 2018 Sep 3. PMID: 30190207; PMCID: PMC6197735.
  39. Soendergaard C, Seidelin JB, Steenholdt C, Nielsen OH. Putative biomarkers of vedolizumab resistance and underlying inflammatory pathways involved in IBD. BMJ Open Gastroenterol. 2018 May 31;5(1):e000208. doi: 10.1136/bmjgast-2018-000208. PMID: 29915667; PMCID: PMC6001911.
  40. Boyd M, Thodberg M, Vitezic M, Bornholdt J, Vitting-Seerup K, Chen Y, Coskun M, Li Y, Lo BZS, Klausen P, Jan Schweiger P, Pedersen AG, Rapin N, Skovgaard K, Dahlgaard K, Andersson R, Terkelsen TB, Lilje B, Troelsen JT, Petersen AM, Jensen KB, Gögenur I, Thielsen P, Seidelin JB, Nielsen OH, Bjerrum JT, Sandelin A. Characterization of the enhancer and promoter landscape of inflammatory bowel disease from human colon biopsies. Nat Commun. 2018 Apr 25;9(1):1661. doi: 10.1038/s41467-018-03766-z. PMID: 29695774; PMCID: PMC5916929.
  41. Holmberg FE, Seidelin JB, Yin X, Mead BE, Tong Z, Li Y, Karp JM, Nielsen OH. Culturing human intestinal stem cells for regenerative applications in the treatment of inflammatory bowel disease. EMBO Mol Med. 2017 May;9(5):558-570. doi: 10.15252/emmm.201607260. PMID: 28283650; PMCID: PMC5412884.
  42. Blixt T, Gradel KO, Homann C, Seidelin JB, Schønning K, Lester A, Houlind J, Stangerup M, Gottlieb M, Knudsen JD. Asymptomatic Carriers Contribute to Nosocomial Clostridium difficile Infection: A Cohort Study of 4508 Patients. Gastroenterology. 2017 Apr;152(5):1031-1041.e2. doi: 10.1053/j.gastro.2016.12.035. Epub 2017 Jan 5. PMID: 28063955.
  43. Chen Y, Salem M, Boyd M, Bornholdt J, Li Y, Coskun M, Seidelin JB, Sandelin A, Nielsen OH. Relation between NOD2 genotype and changes in innate signaling in Crohn’s disease on mRNA and miRNA levels. NPJ Genom Med. 2017 Feb 8;2:3. doi: 10.1038/s41525-016-0001-4. PMID: 29263823; PMCID: PMC5642384.
    *Corresponding author
  44. Soendergaard C, Kvist PH, Seidelin JB, Pelzer H, Nielsen OH. Systemic and intestinal levels of factor XIII-A: the impact of inflammation on expression in macrophage subtypes. J Gastroenterol. 2016 Aug;51(8):796-807. doi: 10.1007/s00535-015-1152-2. Epub 2015 Dec 11. PMID: 26660730.
  45. Soendergaard C, Nielsen OH, Skak K, Røpke MA, Seidelin JB, Kvist PH. Objective Quantification of Immune Cell Infiltrates and Epidermal Proliferation in Psoriatic Skin: A Comparison of Digital Image Analysis and Manual Counting. Appl Immunohistochem Mol Morphol. 2016 Jul;24(6):453-8. doi: 10.1097/PAI.0000000000000191. PMID: 25906125.
  46. Nielsen OH, Seidelin JB, Ainsworth M, Coskun M. Will novel oral formulations change the management of inflammatory bowel disease? Expert Opin Investig Drugs. 2016 Jun;25(6):709-18. doi: 10.1517/13543784.2016.1165204. Epub 2016 Mar 28. PMID: 26967267.
  47. Rehn M, Krarup PM, Christensen LH, Seidelin JB, Ågren MS, Syk I. GM6001 Increases Anastomotic Leakage following Colonic Obstruction Possibly by Impeding Epithelialization. Surg Infect (Larchmt). 2015 Dec;16(6):702-8. doi: 10.1089/sur.2014.248. Epub 2015 Jul 14. PMID: 26171681; PMCID: PMC4663637.
  48. Salem M, Nielsen OH, Nys K, Yazdanyar S, Seidelin JB. Impact of T300A Variant of ATG16L1 on Antibacterial Response, Risk of Culture Positive Infections, and Clinical Course of Crohn’s Disease. Clin Transl Gastroenterol. 2015 Nov 5;6(11):e122. doi: 10.1038/ctg.2015.47. PMID: 26673830; PMCID: PMC4816087.
  49. Soendergaard C, Nielsen OH, Seidelin JB, Kvist PH, Bjerrum JT. Alpha-1 antitrypsin and granulocyte colony-stimulating factor as serum biomarkers of disease severity in ulcerative colitis. Inflamm Bowel Dis. 2015 May;21(5):1077-88. doi: 10.1097/MIB.0000000000000348. PMID: 25803506.
  50. Salem M, Ammitzboell M, Nys K, Seidelin JB, Nielsen OH. ATG16L1: A multifunctional susceptibility factor in Crohn disease. Autophagy. 2015 Apr 3;11(4):585-94. doi: 10.1080/15548627.2015.1017187. PMID: 25906181; PMCID: PMC4502774.
  51. Salem M, Seidelin JB, Eickhardt S, Alhede M, Rogler G, Nielsen OH. Species- specific engagement of human nucleotide oligomerization domain 2 (NOD)2 and Toll-like receptor (TLR) signalling upon intracellular bacterial infection: role of Crohn’s associated NOD2 gene variants. Clin Exp Immunol. 2015 Mar;179(3):426-34. doi: 10.1111/cei.12471. PMID: 25335775; PMCID: PMC4337675.
  52. Seidelin JB, Coskun M, Kvist PH, Holm TL, Holgersen K, Nielsen OH. IL-33 promotes GATA-3 polarization of gut-derived T cells in experimental and ulcerative colitis. J Gastroenterol. 2015 Feb;50(2):180-90. doi: 10.1007/s00535-014-0982-7. Epub 2014 Aug 12. PMID: 25112700.
  53. Seidelin JB, Larsen S, Linnemann D, Vainer B, Coskun M, Troelsen JT, Nielsen OH. Cellular inhibitor of apoptosis protein 2 controls human colonic epithelial restitution, migration, and Rac1 activation. Am J Physiol Gastrointest Liver Physiol. 2015 Jan 15;308(2):G92-9. doi: 10.1152/ajpgi.00089.2014. Epub 2014 Nov 13. PMID: 25394657
  54. Seidelin JB. Regulation of antiapoptotic and cytoprotective pathways in colonic epithelial cells in ulcerative colitis. Scand J Gastroenterol. 2015;50 Suppl 1:1-29. doi: 10.3109/00365521.2016.1101245. PMID: 26513451.
  55. Boyd M, Coskun M, Lilje B, Andersson R, Hoof I, Bornholdt J, Dahlgaard K, Olsen J, Vitezic M, Bjerrum JT, Seidelin JB, Nielsen OH, Troelsen JT, Sandelin A. Identification of TNF-α-responsive promoters and enhancers in the intestinal epithelial cell model Caco-2. DNA Res. 2014 Dec;21(6):569-83. doi: 10.1093/dnares/dsu022. Epub 2014 Jul 2. PMID: 24990076; PMCID: PMC4263293.
  56. Pedersen J, LaCasse EC, Seidelin JB, Coskun M, Nielsen OH. Inhibitors of apoptosis (IAPs) regulate intestinal immunity and inflammatory bowel disease (IBD) inflammation. Trends Mol Med. 2014 Nov;20(11):652-65. doi: 10.1016/j.molmed.2014.09.006. Epub 2014 Oct 1. PMID: 25282548.
  57. Nielsen OH, Jess T, Bjerrum JT, Seidelin JB. [Ulcerative colitis]. Ugeskr Laeger. 2014 Mar 3;176(10A):V10120611. Danish. PMID: 25350705.
  58. Salem M, Seidelin JB, Rogler G, Nielsen OH. Muramyl dipeptide responsive pathways in Crohn’s disease: from NOD2 and beyond. Cell Mol Life Sci. 2013 Sep;70(18):3391-404. doi: 10.1007/s00018-012-1246-4. Epub 2012 Dec 29. PMID: 23275943.
  59. Coskun M, Bjerrum JT, Seidelin JB, Troelsen JT, Olsen J, Nielsen OH. miR-20b, miR-98, miR-125b-1*, and let-7e* as new potential diagnostic biomarkers in ulcerative colitis. World J Gastroenterol. 2013 Jul 21;19(27):4289-99. doi: 10.3748/wjg.v19.i27.4289. PMID: 23885139; PMCID: PMC3718896.
  60. Seidelin JB, Coskun M, Vainer B, Riis L, Soendergaard C, Nielsen OH. ERK controls epithelial cell death receptor signalling and cellular FLICE-like inhibitory protein (c-FLIP) in ulcerative colitis. J Mol Med (Berl). 2013 Jul;91(7):839-49. doi: 10.1007/s00109-013-1003-7. Epub 2013 Feb 1. PMID: 23371318.
  61. Nielsen OH, Jess T, Bjerrum JT, Seidelin JB. Colitis ulcerosa [Ulcerative colitis]. Ugeskr Laeger. 2013 May 13;175(20):1412-6. Danish. PMID: 23663396.
  62. Soendergaard C, Kvist PH, Seidelin JB, Nielsen OH. Tissue-regenerating functions of coagulation factor XIII. J Thromb Haemost. 2013 May;11(5):806-16. doi: 10.1111/jth.12169. PMID: 23406195.
  63. Seidelin JB, Sträter J, Nielsen OH. Caspase 14 does not influence intestinal epithelial cell differentiation. Cell Death Differ. 2013 Mar;20(3):524. doi: 10.1038/cdd.2012.164. Epub 2013 Jan 4. PMID: 23288023; PMCID: PMC3569993.
  64. Seidelin JB, Coskun M, Nielsen OH. Mucosal healing in ulcerative colitis: pathophysiology and pharmacology. Adv Clin Chem. 2013;59:101-23. doi: 10.1016/b978-0-12-405211-6.00004-8. PMID: 23461134.
  65. Coskun M, Bjerrum JT, Seidelin JB, Nielsen OH. MicroRNAs in inflammatory bowel disease–pathogenesis, diagnostics and therapeutics. World J Gastroenterol. 2012 Sep 14;18(34):4629-34. doi: 10.3748/wjg.v18.i34.4629. PMID: 23002331; PMCID: PMC3442200.
  66. Steenholdt C, Molazahi A, Ainsworth MA, Brynskov J, Østergaard Thomsen O, Seidelin JB. Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study. Scand J Gastroenterol. 2012 May;47(5):518-27. doi: 10.3109/00365521.2012.660541. Epub 2012 Mar 1. PMID: 22375898.
  67. Nielsen OH, Bjerrum JT, Seidelin JB, Nyberg C, Ainsworth M. Biological treatment of Crohn’s disease. Dig Dis. 2012;30 Suppl 3:121-33. doi: 10.1159/000342738. Epub 2013 Jan 3. PMID: 23295703.
  68. Hansen M, Gerds TA, Nielsen OH, Seidelin JB, Troelsen JT, Olsen J. pcaGoPromoter–an R package for biological and regulatory interpretation of principal components in genome-wide gene expression data. PLoS One. 2012;7(2):e32394. doi: 10.1371/journal.pone.0032394. Epub 2012 Feb 27. PMID: 22384239; PMCID: PMC3288097.
  69. Seidelin JB, Rogler G, Nielsen OH. A role for interleukin-33 in T(H)2-polarized intestinal inflammation? Mucosal Immunol. 2011 Sep;4(5):496-502. doi: 10.1038/mi.2011.22. Epub 2011 May 25. PMID: 21613987.
  70. Nielsen OH, Seidelin JB, Munck LK, Rogler G. Use of biological molecules in the treatment of inflammatory bowel disease. J Intern Med. 2011 Jul;270(1):15-28. doi: 10.1111/j.1365-2796.2011.02344.x. Epub 2011 Mar 1. PMID: 21241384.
  71. Thorsteinsdottir S, Gudjonsson T, Nielsen OH, Vainer B, Seidelin JB. Pathogenesis and biomarkers of carcinogenesis in ulcerative colitis. Nat Rev Gastroenterol Hepatol. 2011 Jun 7;8(7):395-404. doi: 10.1038/nrgastro.2011.96. PMID: 21647200.
  72. Coskun M, Olsen J, Seidelin JB, Nielsen OH. MAP kinases in inflammatory bowel disease. Clin Chim Acta. 2011 Mar 18;412(7-8):513-20. doi: 10.1016/j.cca.2010.12.020. Epub 2010 Dec 23. PMID: 21185271.
  73. Seidelin JB, Bjerrum JT, Coskun M, Widjaya B, Vainer B, Nielsen OH. IL-33 is upregulated in colonocytes of ulcerative colitis. Immunol Lett. 2010 Jan 18;128(1):80-5. doi: 10.1016/j.imlet.2009.11.001. Epub 2009 Nov 11. PMID: 19913053.
  74. Widjaya B, Seidelin JB, Olsen J, Nielsen OH. Betydningen af mikroribonukleinsyre for sygdomsudvikling [The role of micro-ribonucleic acid in disease development]. Ugeskr Laeger. 2009 Nov 16;171(47):3441-4. Danish. PMID: 19925731.
  75. Seidelin JB, Broom OJ, Olsen J, Nielsen OH. Evidence for impaired CARD15 signalling in Crohn’s disease without disease linked variants. PLoS One. 2009 Nov 12;4(11):e7794. doi: 10.1371/journal.pone.0007794. PMID: 19907652; PMCID: PMC2771351.
  76. Olsen J, Gerds TA, Seidelin JB, Csillag C, Bjerrum JT, Troelsen JT, Nielsen OH. Diagnosis of ulcerative colitis before onset of inflammation by multivariate modeling of genome-wide gene expression data. Inflamm Bowel Dis. 2009 Jul;15(7):1032-8. doi: 10.1002/ibd.20879. PMID: 19177426.
  77. Rönsholt FF, Seidelin JB, Villumsen S. Samtidig leptospirose og salmonellainfektion [Concurrent leptospirosis and salmonella infection]. Ugeskr Laeger. 2009 May 4;171(19):1607-9. Danish. PMID: 19419644.
  78. Seidelin JB, Bruun NE, Nielsen H. Aeromedical transport after acute myocardial infarction. J Travel Med. 2009 Mar-Apr;16(2):96-100. doi: 10.1111/j.1708-8305.2008.00281.x. PMID: 19335808.
  79. Seidelin JB, Nielsen OH. Epithelial apoptosis: cause or consequence of ulcerative colitis? Scand J Gastroenterol. 2009;44(12):1429-34. doi: 10.3109/00365520903301212. PMID: 19958058.
  80. Seidelin JB, Nielsen OH. Attenuated apoptosis response to Fas-ligand in active ulcerative colitis. Inflamm Bowel Dis. 2008 Dec;14(12):1623-9. doi: 10.1002/ibd.20629. PMID: 18680199.
  81. Seidelin JB, Vainer B, Andresen L, Nielsen OH. Upregulation of cIAP2 in regenerating colonocytes in ulcerative colitis. Virchows Arch. 2007 Dec;451(6):1031-8. doi: 10.1007/s00428-007-0517-1. Epub 2007 Oct 31. PMID: 17972100.
  82. Seidelin JB, Nielsen OH. Expression profiling of apoptosis-related genes in enterocytes isolated from patients with ulcerative colitis. APMIS. 2006 Jul- Aug;114(7-8):508-17. doi: 10.1111/j.1600-0463.2006.apm_116.x. PMID: 16907856.
  83. Ferrero-Miliani L, Seidelin JB, Nielsen OH. Regulering af cytokindannelse ved inflammatoriske tarmsygdomme [Regulation of cytokine production in inflammatory bowel disease]. Ugeskr Laeger. 2006 May 8;168(19):1847-50. Danish. PMID: 16756799.
  84. Seidelin JB, Nielsen OH. Transdermal nikotinbehandling af colitis ulcerosa: gennemgang af et Cochrane-review [Transdermal nicotine treatment of ulcerative colitis: a survey of a Cochrane review]. Ugeskr Laeger. 2006 Feb 13;168(7):674-7. Danish. PMID: 16494804.
  85. Kirman I, Whelan RL, Jain S, Nielsen SE, Seidelin JB, Nielsen OH. Insulin- like growth factor binding protein 3 in inflammatory bowel disease. Dig Dis Sci. 2005 Apr;50(4):780-4. doi: 10.1007/s10620-005-2573-1. PMID: 15844718.
  86. Seidelin JB, Nielsen OH. Continuous cytokine exposure of colonic epithelial cells induces DNA damage. Eur J Gastroenterol Hepatol. 2005 Mar;17(3):363-9. doi: 10.1097/00042737-200503000-00017. PMID: 15716663.
  87. Seidelin JB, Bech J. Visioner for medicinsk og uddannelsesmaessig brug af den personlige digitale assistent [Visions concerning medical and educational use of personal digital assistant]. Ugeskr Laeger. 2004 Nov 1;166(45):4019. Danish. PMID: 15565956.
  88. Pedersen N, Larsen S, Seidelin JB, Nielsen OH. Alcohol modulates circulating levels of interleukin-6 and monocyte chemoattractant protein-1 in chronic pancreatitis. Scand J Gastroenterol. 2004 Mar;39(3):277-82. doi: 10.1080/00365520310008296. PMID: 15074399.
  89. Seidelin JB. Colonic epithelial cell turnover: possible implications for ulcerative colitis and cancer initiation. Scand J Gastroenterol. 2004 Mar;39(3):201-11. doi: 10.1080/00365520310005974. PMID: 15074387.
  90. Seidelin JB, Jäättelä M, Nielsen OH. Continuous interferon-gamma or tumor necrosis factor-alpha exposure of enterocytes attenuates cell death responses. Cytokine. 2004 Aug 21-Sep 7;27(4-5):113-9. doi: 10.1016/j.cyto.2004.04.001. PMID: 15271377.
  91. Seidelin JB, Horn T, Nielsen OH. Simple and efficient method for isolation and cultivation of endoscopically obtained human colonocytes. Am J Physiol Gastrointest Liver Physiol. 2003 Dec;285(6):G1122-8. doi: 10.1152/ajpgi.00533.2002. PMID: 14613919.
  92. Vainer B, Sørensen S, Seidelin J, Nielsen OH, Horn T. Expression of ICAM-1 in colon epithelial cells: an ultrastructural study performed on in vivo and in vitro models. Virchows Arch. 2003 Dec;443(6):774-81. doi: 10.1007/s00428-003-0900-5. Epub 2003 Oct 16. PMID: 14564519.
  93. Seidelin JB, Nielsen OH. Apoptose ved kronisk inflammatorisk tarmsygdom. Betydning for patogenese og behandling [Apoptosis in chronic inflammatory bowel disease. The importance for pathogenesis and treatment]. Ugeskr Laeger. 2003 Feb 17;165(8):790-2. Danish. PMID: 12625119.
  94. Seidelin JB, Nielsen OH, Strøm J. Soluble L-selectin levels predict survival in sepsis. Intensive Care Med. 2002 Nov;28(11):1613-8. doi: 10.1007/s00134-002-1501-5. Epub 2002 Sep 21. PMID: 12415449.
  95. Nielsen OH, Nielsen SE, Seidelin JB. Recent therapeutic advances in inflammatory bowel disease. IDrugs. 2002 Jul;5(7):618-22. PMID: 14686335.
  96. Tadjali M, Seidelin JB, Olsen J, Troelsen JT. Transcriptome changes during intestinal cell differentiation. Biochim Biophys Acta. 2002 Apr 3;1589(2):160-7. doi: 10.1016/s0167-4889(02)00170-2. PMID: 12007791.
  97. Seidelin JB, Nielsen OH. Digestive Disease Week 2001. Novel therapeutic principles in inflammatory bowel disease. 20-23 May 2001, Atlanta, GA, USA. IDrugs. 2001 Aug;4(8):874-8. PMID: 15973578.
  98. Nielsen OH, Vainer B, Madsen SM, Seidelin JB, Heegaard NH. Established and emerging biological activity markers of inflammatory bowel disease. Am J Gastroenterol. 2000 Feb;95(2):359-67. doi: 10.1111/j.1572-0241.2000.t01-1-01790.x. PMID: 10685736.
  99. Seidelin JB, Vainer B, Horn T, Nielsen OH. Circulating L-selectin levels and endothelial CD34 expression in inflammatory bowel disease. Am J Gastroenterol. 1998 Oct;93(10):1854-9. doi: 10.1111/j.1572-0241.1998.538_f.x. PMID: 9772044.
  100. Kragh J, Seidelin J, Bolwig TG. Seizure threshold to lidocaine is decreased following repeated ECS (electroconvulsive shock). Psychopharmacology (Berl). 1993;111(4):495-8. doi: 10.1007/BF02253542. PMID: 7870993.